Comparison of immunosuppression and anti-CD20 treatment in caplacizumab and noncaplacizumab cohorts
| . | Caplacizumab . | Noncaplacizumab . | P value . |
|---|---|---|---|
| Median days of IV methylprednisolone only (IQR) | 2 (1-2) | 2 (2-3.5) | .1 |
| Median dose of IV methylprednisolone (IQR), g | 1.5 (0.875-2) | 2 (1.25-2.25) | .2 |
| Number of patients receiving steroids∗ | 62/64 | 47/50 | .65 |
| Days of prednisolone wean (IQR) | 13 (9-19) | 16 (10-18) | .4 |
| Number of patients receiving rituximab | 61/64 | 43/50† | .1 |
| Median number of rituximab doses (range) | 6 (4-8) | 4 (1-8) | .05 |
| Number of patients receiving additional immunosuppression (%)‡ | 21/64 (33) | 12/50 (24) | .5 |
| . | Caplacizumab . | Noncaplacizumab . | P value . |
|---|---|---|---|
| Median days of IV methylprednisolone only (IQR) | 2 (1-2) | 2 (2-3.5) | .1 |
| Median dose of IV methylprednisolone (IQR), g | 1.5 (0.875-2) | 2 (1.25-2.25) | .2 |
| Number of patients receiving steroids∗ | 62/64 | 47/50 | .65 |
| Days of prednisolone wean (IQR) | 13 (9-19) | 16 (10-18) | .4 |
| Number of patients receiving rituximab | 61/64 | 43/50† | .1 |
| Median number of rituximab doses (range) | 6 (4-8) | 4 (1-8) | .05 |
| Number of patients receiving additional immunosuppression (%)‡ | 21/64 (33) | 12/50 (24) | .5 |
Methylprednisolone and/or prednisolone.
Includes 2 patients who died (1 patient received 2 doses and another patient received 1 dose). Five patients had antiretroviral disease, 1 patient had viral encephalitis, and clinical information was lacking in 1 patient.
Caplacizumab-treated cohort: received MMF and 2 patients additionally received bortezomib. Non-caplacizumab-treated cohort: majority received MMF except 3 patients who received bortezomib.